Exhibit 99.2
Schering-Plough Corporation | ||||||||||||||||
Statements of Consolidated Income | ||||||||||||||||
(Dollars in Millions, except EPS) | ||||||||||||||||
2002 | 2001 | |||||||||||||||
1st | 2nd | 6 | 3rd | 9 | 4th | 1st | 2nd | 6 | 3rd | 9 | 4th | 4th Qtr. | 12 Mos. | |||
Qtr. | Qtr. | Mos. | Qtr. | Mos. | Qtr. | Year | Qtr. | Qtr. | Mos. | Qtr. | Mos. | Qtr. | Year | vs | vs | |
$ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | 4th Qtr. | 12 Mos. | |
Net Sales | 2,556 | 2,833 | 5,389 | 2,421 | 7,810 | 2,370 | 10,180 | 2,306 | 2,618 | 4,924 | 2,377 | 7,301 | 2,461 | 9,762 | (4%) | 4% |
Cost of Sales | 579 | 675 | 1,254 | 644 | 1,898 | 607 | 2,505 | 470 | 535 | 1,005 | 486 | 1,490 | 588 | 2,078 | 3% | 21% |
Gross Margin | 1,977 | 2,158 | 4,135 | 1,777 | 5,912 | 1,763 | 7,675 | 1,836 | 2,083 | 3,919 | 1,891 | 5,811 | 1,873 | 7,684 | (6%) | 0% |
Total SG&A | 919 | 995 | 1,914 | 870 | 2,784 | 897 | 3,681 | 839 | 955 | 1,794 | 830 | 2,624 | 820 | 3,444 | 10% | 7% |
Research & Development | 305 | 357 | 662 | 354 | 1,017 | 409 | 1,425 | 289 | 334 | 624 | 310 | 934 | 378 | 1,312 | 8% | 9% |
Other, Net* | (26) | (16) | (41) | (4) | (47) | (98) | (144) | (25) | (29) | (55) | (30) | (84) | 489 | 405 | N/M | N/M |
Income before Income Taxes | 779 | 822 | 1,600 | 557 | 2,158 | 555 | 2,713 | 733 | 823 | 1,556 | 781 | 2,337 | 186 | 2,523 | N/M | 8% |
Income Taxes | 179 | 189 | 368 | 128 | 496 | 127 | 624 | 169 | 189 | 358 | 180 | 537 | 43 | 580 | N/M | 8% |
Net Income | 600 | 633 | 1,232 | 429 | 1,662 | 428 | 2,089 | 564 | 634 | 1,198 | 601 | 1,800 | 143 | 1,943 | N/M | 8% |
Diluted Earnings per Common Share | 0.41 | 0.43 | 0.84 | 0.29 | 1.13 | 0.29 | 1.42 | 0.38 | 0.43 | 0.81 | 0.41 | 1.22 | 0.10 | 1.32 | N/M | 8% |
Avg. Shares Outstanding- Diluted | 1,471 | 1,470 | 1,470 | 1,469 | 1,470 | 1,469 | 1,470 | 1,472 | 1,470 | 1,471 | 1,470 | 1,470 | 1,470 | 1,470 | ||
Actual Shares Outstanding | 1,466 | 1,466 | 1,466 | 1,467 | 1,467 | 1,468 | 1,468 | 1,463 | 1,463 | 1,463 | 1,464 | 1,464 | 1,465 | 1,465 | ||
Ratios To Net Sales | ||||||||||||||||
Net Sales | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | ||
Cost of Sales | 22.6% | 23.8% | 23.3% | 26.6% | 24.3% | 25.6% | 24.6% | 20.4% | 20.4% | 20.4% | 20.4% | 20.4% | 23.9% | 21.3% | ||
Gross Margin | 77.4% | 76.2% | 76.7% | 73.4% | 75.7% | 74.4% | 75.4% | 79.6% | 79.6% | 79.6% | 79.6% | 79.6% | 76.1% | 78.7% | ||
Total SG&A | 35.9% | 35.1% | 35.5% | 35.9% | 35.6% | 37.9% | 36.2% | 36.4% | 36.5% | 36.4% | 34.9% | 35.9% | 33.3% | 35.3% | ||
Research & Development | 11.9% | 12.6% | 12.3% | 14.6% | 13.0% | 17.2% | 14.0% | 12.5% | 12.8% | 12.7% | 13.1% | 12.8% | 15.4% | 13.4% | ||
Income Before Income Taxes | 30.5% | 29.0% | 29.7% | 23.0% | 27.6% | 23.4% | 26.7% | 31.8% | 31.4% | 31.6% | 32.8% | 32.0% | 7.6% | 25.8% | ||
Income Taxes | 7.0% | 6.7% | 6.8% | 5.3% | 6.4% | 5.4% | 6.1% | 7.3% | 7.2% | 7.3% | 7.6% | 7.4% | 1.7% | 5.9% | ||
Net Income | 23.5% | 22.3% | 22.9% | 17.7% | 21.3% | 18.0% | 20.5% | 24.5% | 24.2% | 24.3% | 25.3% | 24.6% | 5.8% | 19.9% | ||
* 4th quarter and year-to-date 2001 includes a $500 million provision for a consent decree payment. | ||||||||||||||||
Notes: Certain amounts in prior periods have been reclassified from Selling, General and Administrative expenses to Net Sales to comply with EITF No. 00-25, "Vendor Income | ||||||||||||||||
Statement Characterization of Consideration Paid to a Reseller of the Vendor's Products." | ||||||||||||||||
All figures rounded. Totals may not add due to rounding. N/M - not a meaningful percentage. | ||||||||||||||||
SCHERING-PLOUGH CORPORATION | ||||||||||||||||
ALLERGY/RESPIRATORY PRODUCT SALES | ||||||||||||||||
(Dollars in Millions) | ||||||||||||||||
2002 | 2001 | |||||||||||||||
1st | 2nd | 6 | 3rd | 9 | 4th | 1st | 2nd | 6 | 3rd | 9 | 4th | 4th Qtr. | 12 Mos. | |||
Qtr. | Qtr. | Mos. | Qtr. | Mos. | Qtr. | Year | Qtr. | Qtr. | Mos. | Qtr. | Mos. | Qtr. | Year | vs | vs | |
$ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | 4th Qtr. | 12 Mos. | |
U.S: | 805 | 899 | 1,703 | 579 | 2,282 | 124 | 2,406 | 719 | 1,006 | 1,725 | 937 | 2,662 | 725 | 3,387 | (83%) | (29%) |
Clarinex | 70 | 137 | 207 | 132 | 340 | 146 | 485 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | N/M | N/M |
Claritin Rx ** | 392 | 479 | 871 | 243 | 1,114 | (128) | 986 | 504 | 514 | 1,018 | 432 | 1,449 | 499 | 1,948 | N/M | (49%) |
Claritin D Rx ** | 173 | 198 | 371 | 60 | 431 | 7 | 438 | 106 | 268 | 375 | 297 | 671 | 96 | 768 | (93%) | (43%) |
Total Claritin Family Rx ** | 565 | 677 | 1,242 | 303 | 1,545 | (121) | 1,424 | 610 | 782 | 1,393 | 728 | 2,121 | 595 | 2,716 | N/M | (48%) |
Nasonex | 101 | 54 | 155 | 124 | 279 | 80 | 359 | 63 | 145 | 208 | 107 | 316 | 75 | 391 | 7% | (8%) |
Proventil | 59 | 30 | 89 | 22 | 111 | 17 | 128 | 40 | 66 | 106 | 88 | 194 | 36 | 230 | (52%) | (44%) |
Other | 10 | 1 | 10 | (2) | 7 | 2 | 10 | 6 | 13 | 18 | 14 | 31 | 19 | 50 | (89%) | (80%) |
International: | 209 | 249 | 458 | 226 | 684 | 214 | 898 | 208 | 239 | 447 | 184 | 631 | 199 | 830 | 8% | 8% |
Clarinex * | 14 | 36 | 50 | 32 | 82 | 31 | 112 | * | * | * | * | * | * | * | N/M | N/M |
Claritin Rx | 64 | 90 | 154 | 77 | 231 | 42 | 274 | 79 | 119 | 198 | 77 | 275 | 61 | 336 | (31%) | (19%) |
Claritin D Rx | 30 | 25 | 55 | 22 | 77 | 28 | 104 | 28 | 24 | 52 | 23 | 75 | 32 | 107 | (14%) | (2%) |
Total Claritin Family Rx | 94 | 115 | 209 | 99 | 308 | 70 | 378 | 108 | 143 | 250 | 99 | 350 | 93 | 443 | (25%) | (15%) |
Nasonex | 37 | 47 | 83 | 36 | 119 | 45 | 164 | 29 | 37 | 66 | 29 | 95 | 39 | 134 | 17% | 23% |
Other | 64 | 51 | 116 | 59 | 175 | 68 | 244 | 71 | 59 | 131 | 56 | 186 | 67 | 253 | 1% | (4%) |
Total: | 1,014 | 1,147 | 2,161 | 805 | 2,966 | 338 | 3,304 | 927 | 1,244 | 2,171 | 1,121 | 3,293 | 924 | 4,217 | (63%) | (22%) |
Clarinex * | 85 | 173 | 258 | 164 | 422 | 176 | 598 | * | * | * | * | * | * | * | N/M | N/M |
Claritin Rx ** | 456 | 568 | 1,025 | 321 | 1,346 | (85) | 1,260 | 583 | 633 | 1,216 | 508 | 1,725 | 560 | 2,285 | N/M | (45%) |
Claritin D Rx ** | 203 | 223 | 426 | 82 | 508 | 35 | 542 | 135 | 292 | 427 | 319 | 746 | 128 | 875 | (73%) | (38%) |
Total Claritin Family Rx ** | 659 | 792 | 1,451 | 402 | 1,853 | (51) | 1,802 | 718 | 925 | 1,643 | 828 | 2,471 | 688 | 3,159 | N/M | (43%) |
Nasonex | 138 | 101 | 238 | 160 | 398 | 125 | 523 | 92 | 183 | 274 | 136 | 411 | 114 | 524 | 10% | - |
Proventil | 59 | 30 | 89 | 22 | 111 | 17 | 128 | 40 | 66 | 106 | 88 | 194 | 36 | 230 | (52%) | (44%) |
Other | 73 | 51 | 125 | 57 | 182 | 71 | 253 | 77 | 70 | 148 | 69 | 217 | 86 | 304 | (17%) | (17%) |
* International sales of CLARINEX were included in CLARITIN sales in 2001. | ||||||||||||||||
** Claritin OTC sales are now reported in the OTC category (see page 6) . | ||||||||||||||||
Notes: All figures rounded. Totals may not add due to rounding. N/M - not a meaningful percentage. | ||||||||||||||||
SCHERING-PLOUGH CORPORATION | ||||||||||||||||
ANTI-INFECTIVE/ANTICANCER PRODUCT SALES | ||||||||||||||||
(Dollars in Millions) | ||||||||||||||||
2002 | 2001 | |||||||||||||||
1st | 2nd | 6 | 3rd | 9 | 4th | 1st | 2nd | 6 | 3rd | 9 | 4th | 4th Qtr. | 12 Mos. | |||
Qtr. | Qtr. | Mos. | Qtr. | Mos. | Qtr. | Year | Qtr. | Qtr. | Mos. | Qtr. | Mos. | Qtr. | Year | vs | vs | |
$ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | 4th Qtr. | 12 Mos. | |
U.S.: | 411 | 420 | 830 | 472 | 1,302 | 580 | 1,881 | 251 | 194 | 445 | 177 | 622 | 334 | 956 | 74% | 97% |
Intron franchise* | 342 | 377 | 719 | 426 | 1,145 | 544 | 1,689 | 187 | 147 | 334 | 129 | 463 | 287 | 750 | 90% | N/M |
Temodar | 34 | 47 | 80 | 42 | 122 | 36 | 158 | 26 | 26 | 51 | 23 | 75 | 24 | 99 | 51% | 60% |
Other | 35 | (4) | 31 | 4 | 35 | - | 34 | 38 | 21 | 60 | 25 | 84 | 23 | 107 | N/M | (68%) |
International: | 387 | 471 | 858 | 485 | 1,343 | 508 | 1,851 | 274 | 316 | 590 | 319 | 909 | 409 | 1,317 | 24% | 41% |
Intron franchise* | 215 | 282 | 497 | 277 | 774 | 273 | 1,047 | 139 | 169 | 307 | 172 | 479 | 218 | 697 | 26% | 50% |
Remicade | 60 | 76 | 137 | 92 | 228 | 109 | 337 | 27 | 36 | 63 | 42 | 105 | 61 | 166 | 78% | N/M |
Temodar | 25 | 28 | 53 | 34 | 87 | 33 | 120 | 17 | 18 | 35 | 21 | 57 | 25 | 82 | 33% | 47% |
Other | 87 | 85 | 171 | 82 | 254 | 93 | 347 | 91 | 93 | 185 | 84 | 268 | 105 | 372 | (11%) | (7%) |
Total: | 797 | 891 | 1,688 | 957 | 2,645 | 1,088 | 3,733 | 525 | 510 | 1,035 | 496 | 1,531 | 742 | 2,273 | 47% | 64% |
Intron franchise* | 556 | 659 | 1,216 | 703 | 1,919 | 817 | 2,736 | 326 | 315 | 641 | 301 | 942 | 504 | 1,447 | 62% | 89% |
Remicade | 60 | 76 | 137 | 92 | 228 | 109 | 337 | 27 | 36 | 63 | 42 | 105 | 61 | 166 | 78% | N/M |
Temodar | 59 | 74 | 133 | 76 | 209 | 69 | 278 | 43 | 44 | 87 | 45 | 132 | 49 | 180 | 42% | 54% |
Other | 122 | 82 | 202 | 86 | 289 | 93 | 382 | 129 | 115 | 244 | 108 | 352 | 128 | 480 | (27%) | (20%) |
* The INTRON franchise consists of INTRON A, PEG-INTRON (monotherapy and in combination with REBETOL), and REBETRON Combination Therapy. | ||||||||||||||||
Notes: All figures rounded. Totals may not add due to rounding. N/M - not a meaningful percentage. | ||||||||||||||||
SCHERING-PLOUGH CORPORATION | ||||||||||||||||
CARDIOVASCULAR PRODUCT SALES | ||||||||||||||||
(Dollars in Millions) | ||||||||||||||||
2002 | 2001 | |||||||||||||||
1st | 2nd | 6 | 3rd | 9 | 4th | 1st | 2nd | 6 | 3rd | 9 | 4th | 4th Qtr. | 12 Mos. | |||
Qtr. | Qtr. | Mos. | Qtr. | Mos. | Qtr. | Year | Qtr. | Qtr. | Mos. | Qtr. | Mos. | Qtr. | Year | vs | vs | |
$ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | 4th Qtr. | 12 Mos. | |
U.S.: | 95 | 89 | 184 | 74 | 258 | 78 | 336 | 142 | 109 | 251 | 133 | 384 | 134 | 519 | (42%) | (35%) |
Integrilin | 62 | 71 | 134 | 72 | 206 | 77 | 283 | 34 | 61 | 95 | 53 | 148 | 60 | 208 | 28% | 36% |
K-Dur | 19 | 5 | 24 | (2) | 21 | (7) | 14 | 74 | 19 | 92 | 59 | 151 | 62 | 213 | N/M | (93%) |
Nitro-Dur | 10 | 6 | 16 | 1 | 17 | 7 | 24 | 12 | 13 | 25 | 12 | 37 | 8 | 45 | (18%) | (47%) |
Other | 4 | 7 | 10 | 3 | 14 | 1 | 15 | 22 | 16 | 39 | 9 | 48 | 4 | 53 | (75%) | (72%) |
International: | 22 | 26 | 48 | 26 | 74 | 24 | 97 | 22 | 25 | 46 | 27 | 73 | 32 | 105 | (26%) | (7%) |
Integrilin | 6 | 6 | 12 | 5 | 17 | 4 | 20 | 4 | 6 | 10 | 6 | 16 | 7 | 23 | (46%) | (10%) |
K-Dur | - | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 1 | 1 | - | 2 | - | 2 | 40% | (2%) |
Nitro-Dur | 13 | 16 | 29 | 16 | 45 | 17 | 62 | 14 | 16 | 31 | 18 | 49 | 20 | 69 | (17%) | (10%) |
Other | 3 | 3 | 6 | 4 | 10 | 2 | 13 | 3 | 2 | 4 | 3 | 6 | 5 | 11 | (60%) | 18% |
Total: | 117 | 115 | 232 | 99 | 331 | 102 | 433 | 164 | 134 | 297 | 160 | 457 | 166 | 623 | (39%) | (30%) |
Integrilin | 68 | 78 | 146 | 77 | 223 | 81 | 304 | 38 | 67 | 105 | 59 | 164 | 67 | 231 | 21% | 32% |
K-Dur | 20 | 5 | 25 | (2) | 23 | (7) | 16 | 74 | 19 | 94 | 59 | 153 | 63 | 216 | N/M | (92%) |
Nitro-Dur | 23 | 22 | 45 | 17 | 62 | 23 | 85 | 26 | 29 | 55 | 30 | 85 | 28 | 113 | (18%) | (25%) |
Other | 6 | 10 | 16 | 7 | 23 | 5 | 28 | 26 | 19 | 43 | 12 | 55 | 8 | 63 | (38%) | (56%) |
Notes: All figures rounded. Totals may not add due to rounding. N/M - not a meaningful percentage. | ||||||||||||||||
SCHERING-PLOUGH CORPORATION | ||||||||||||||||
DERMATOLOGICALS, OTHER PHARMACEUTICAL, TOTAL PHARMACEUTICAL | ||||||||||||||||
(Dollars in Millions) | ||||||||||||||||
2002 | 2001 | |||||||||||||||
1st | 2nd | 6 | 3rd | 9 | 4th | 1st | 2nd | 6 | 3rd | 9 | 4th | 4th Qtr. | 12 Mos. | |||
Qtr. | Qtr. | Mos. | Qtr. | Mos. | Qtr. | Year | Qtr. | Qtr. | Mos. | Qtr. | Mos. | Qtr. | Year | vs | vs | |
$ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | 4th Qtr. | 12 Mos. | |
U.S. | 32 | 20 | 52 | 27 | 79 | 53 | 132 | 52 | 82 | 133 | 57 | 190 | 23 | 214 | N/M | (38%) |
International | 88 | 92 | 180 | 94 | 274 | 104 | 378 | 90 | 95 | 185 | 93 | 278 | 102 | 380 | 2% | - |
Dermatologicals: | 120 | 112 | 232 | 121 | 353 | 158 | 511 | 142 | 176 | 318 | 150 | 468 | 126 | 593 | 26% | (14%) |
Other Pharm: | 159 | 209 | 368 | 158 | 526 | 239 | 764 | 190 | 163 | 354 | 150 | 502 | 153 | 656 | 56% | 16% |
U.S. | 1,337 | 1,441 | 2,778 | 1,156 | 3,934 | 885 | 4,819 | 1,166 | 1,394 | 2,560 | 1,294 | 3,854 | 1,222 | 5,076 | (28%) | (5%) |
International | 870 | 1,033 | 1,903 | 984 | 2,887 | 1,040 | 3,926 | 782 | 833 | 1,615 | 783 | 2,397 | 889 | 3,286 | 17% | 19% |
Total Pharm: | 2,207 | 2,474 | 4,681 | 2,140 | 6,821 | 1,925 | 8,745 | 1,948 | 2,227 | 4,175 | 2,077 | 6,251 | 2,111 | 8,362 | (9%) | 5% |
Notes: Excluding exchange, international pharmaceutical sales increased 11 percent for the fourth quarter and 17 percent for the full year of 2002. | ||||||||||||||||
Certain amounts in prior periods have been reclassified from Selling, General and Administrative expenses to Net Sales to comply with EITF No. 00-25, "Vendor | ||||||||||||||||
Income Statement Characterization of Consideration Paid to a Reseller of the Vendor's Products." | ||||||||||||||||
All figures rounded. Totals may not add due to rounding. N/M - not a meaningful percentage. | ||||||||||||||||
SCHERING-PLOUGH CORPORATION | ||||||||||||||||
ANIMAL HEALTH, OTC, FOOT CARE, SUN CARE & CONSOLIDATED SALES | ||||||||||||||||
(Dollars in Millions) | ||||||||||||||||
2002 | 2001 | |||||||||||||||
1st | 2nd | 6 | 3rd | 9 | 4th | 1st | 2nd | 6 | 3rd | 9 | 4th | 4th Qtr. | 12 Mos. | |||
Qtr. | Qtr. | Mos. | Qtr. | Mos. | Qtr. | Year | Qtr. | Qtr. | Mos. | Qtr. | Mos. | Qtr. | Year | vs | vs | |
$ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | 4th Qtr. | 12 Mos. | |
U.S. | 57 | 49 | 106 | 59 | 165 | 62 | 227 | 54 | 58 | 112 | 60 | 172 | 78 | 250 | (21%) | (9%) |
International | 94 | 122 | 215 | 103 | 318 | 131 | 450 | 99 | 112 | 212 | 110 | 321 | 123 | 444 | 7% | 1% |
Animal Health: | 150 | 171 | 321 | 162 | 483 | 193 | 677 | 153 | 170 | 323 | 169 | 493 | 201 | 694 | (4%) | (2%) |
Foot Care: | 76 | 83 | 160 | 65 | 225 | 66 | 290 | 76 | 93 | 169 | 77 | 246 | 64 | 310 | 2% | (6%) |
OTC: | 41 | 39 | 79 | 40 | 119 | 155 | 275 | 53 | 40 | 93 | 42 | 135 | 53 | 188 | N/M | 46% |
OTC Claritin | 0 | 0 | 0 | 0 | 0 | 105 | 105 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | N/M | N/M |
Other OTC | 41 | 39 | 79 | 40 | 119 | 50 | 170 | 53 | 40 | 93 | 42 | 135 | 53 | 188 | (6%) | (10%) |
Sun Care: | 82 | 66 | 148 | 14 | 162 | 31 | 193 | 76 | 88 | 164 | 12 | 176 | 32 | 208 | - | (7%) |
U.S. | 1,577 | 1,659 | 3,236 | 1,324 | 4,560 | 1,201 | 5,761 | 1,411 | 1,648 | 3,059 | 1,472 | 4,531 | 1,442 | 5,973 | (17%) | (4%) |
International | 979 | 1,175 | 2,153 | 1,096 | 3,250 | 1,169 | 4,419 | 895 | 970 | 1,865 | 905 | 2,770 | 1,019 | 3,789 | 15% | 17% |
Total Consolidated: | 2,556 | 2,833 | 5,389 | 2,421 | 7,810 | 2,370 | 10,180 | 2,306 | 2,618 | 4,924 | 2,377 | 7,301 | 2,461 | 9,762 | (4%) | 4% |
Notes: Excluding exchange, consolidated sales decreased 6 percent for the fourth quarter and increased 3 percent for the full year of 2002. | ||||||||||||||||
Certain amounts in prior periods have been reclassified from Selling, General and Administrative expenses to Net Sales to comply with EITF No. 00-25, "Vendor Income | ||||||||||||||||
Statement Characterization of Consideration Paid to a Reseller of the Vendor's Products." | ||||||||||||||||
All figures rounded. Totals may not add due to rounding. N/M - not a meaningful percentage. | ||||||||||||||||
MISCELLANEOUS DATA | ||||||||||||||
(Dollars in Millions) | ||||||||||||||
2002 | 2001 | |||||||||||||
1st | 2nd | 6 | 3rd | 9 | 4th | 1st | 2nd | 6 | 3rd | 9 | 4th | |||
Qtr. | Qtr. | Mos. | Qtr. | Mos. | Qtr. | Year | Qtr. | Qtr. | Mos. | Qtr. | Mos. | Qtr. | Year | |
$ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | $ | |
Consolidated Sales | ||||||||||||||
Growth Rates: | ||||||||||||||
As Reported | 11% | 8% | 9% | 2% | 7% | (4%) | 4% | (3%) | - % | (1%) | - % | (1%) | 2% | - % |
Excluding Exchange | 13% | 8% | 10% | (1%) | 7% | (6%) | 3% | (1%) | (3%) | 1% | 2% | 1% | 3% | 2% |
Other, Net | ||||||||||||||
Interest Income | $17 | $18 | $35 | $18 | $53 | $22 | $75 | $38 | $32 | $70 | $29 | $99 | $22 | $121 |
Interest Expense | (5) | (12) | (17) | (4) | (21) | (6) | (28) | (11) | (12) | (22) | (8) | (30) | (10) | (40) |
FX Gains/(Losses) | 2 | 2 | 4 | (1) | 4 | (2) | 2 | (6) | 2 | (4) | (3) | (7) | 4 | (4) |
Other Income/(Expense)* | 12 | 8 | 19 | (9) | 11 | 84 | 95 | 4 | 7 | 11 | 12 | 22 | (505) | (482) |
Total - Other, Net | $26 | $16 | $41 | $4 | $47 | $98 | $144 | $25 | $29 | $55 | $30 | $84 | ($489) | ($405) |
Effective Tax Rate | 23.0% | 23.0% | 23.0% | 23.0% | 23.0% | 23.0% | 23.0% | 23.0% | 23.0% | 23.0% | 23.0% | 23.0% | 23.0% | 23.0% |
* 4th quarter and year-to-date 2001 includes a $500 million provision for the consent decree payments. | ||||||||||||||
Notes: Certain amounts in prior periods have been reclassified from Selling, General and Administrative expenses to Net Sales to comply with EITF No. 00-25, | ||||||||||||||
"Vendor Income Statement Characterization of Consideration Paid to a Reseller of the Vendor's Products." | ||||||||||||||
All figures rounded. Totals may not add due to rounding. N/M - not a meaningful percentage. | ||||||||||||||
4th Quarter 2002 | 12 Mos. 2002 | |||||||||||||
Actual Shares Outstanding | Actual Shares Outstanding | 4th Quarter Highlights | ||||||||||||
As of 9/30/02 | 1,466,514,892 | As of 12/31/01 | 1,465,399,110 | - ZETIA approved in U.S. and Germany for | ||||||||||
cholesterol reduction | ||||||||||||||
Shares Issued | Shares Issued | - Prescription-strength CLARITIN approved in | ||||||||||||
Employee Stock Programs | 1,568,757 | Employee Stock Programs | 2,684,539 | U.S. for OTC sales | ||||||||||
- Sold U.S. rights for SUBOXONE and SUBUTEX | ||||||||||||||
Shares Repurchased | 0 | Shares Repurchased | 0 | back to Reckitt Benckiser | ||||||||||
- Settled royalty dispute with Biogen regarding | ||||||||||||||
As of 12/31/02 | 1,468,083,649 | As of 12/31/02 | 1,468,083,649 | inteferon products | ||||||||||
- Gained U.S. marketing rights to FORADIL | ||||||||||||||
AEROLIZER for respiratory disease from | ||||||||||||||
Novartis | ||||||||||||||
Geraldine U. Foster | 908-298-7410 | |||||||||||||
Lisa W. DeBerardine | 908-298-7437 | |||||||||||||
Janet M. Barth | 908-298-7417 | |||||||||||||
Last Updated on 1/22/03
By Schering-Plough